Clinical trials: CRS
Chronic Rhinosinusitis (CRS)
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray
The goal of this clinical study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VVN432 Nasal Spray in healthy volunteers (Phase Ia) and in patients with chronic rhinosinusitis (Phase 1b).
- Trial name
- NCT07259538
- Testing
- 0.5% VVN432 Nasal Spray, 1% VVN432 Nasal Spray, Vehicle
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VivaVision Biotech, Inc